Industry Newsbiotechclinical trialsardelyxgastrointestinal
Ardelyx Reports Strong 2025 Revenue And Outlook
4.9
Ardelyx, Inc. reported preliminary unaudited product revenue results for fourth quarter and full-year 2025, saying Ibsrela revenue rose 73% year-over-year and Xphozah sales increased. The company announced a Phase 3 program for Ibsrela in chronic idiopathic constipation, initiation of next-generation NHE3 inhibitor RDX10531, and guidance anticipating continued growth and Ibsrela peak sales exceeding $1 billion, with patent protection through 2041.
Key Points
- 1Reported Ibsrela revenue increased 73% year-over-year in 2025, with sustained Xphozah patient access and product momentum.
- 2Initiated Phase 3 trial in chronic idiopathic constipation, potentially expanding addressable market and long-term sales opportunity.
- 3Positions company for >$1B peak Ibsrela sales with patent protection to 2041, supporting continued commercial investment.
Scoring Rationale
Solid company updates and Phase 3 start drive relevance, but limited industry-wide novelty and low AI/DS relevance.
Sources
Public references used for this report.
Practice with real Health & Insurance data
90 SQL & Python problems · 15 industry datasets
Used by DS/ML engineers at top companies
250 free problems · No credit card
See all Health & Insurance problems